NCT03422081

Growth and Asymmetric diMethylArginine

Validation of the Dosage of Asymmetric Dimethylarginine (ADMA) Plasma in the Assessment of Endothelial Dysfunction During Growth Hormone Deficiency and Intrauterine Growth Retardation

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 23 (actual)
• Sponsor: University Hospital, Lille · Academic / Other
• Sex: All
• Age: 3 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

Principal objective : Validation of a handy biochemical parameter, plasma concentration of Asymmetric DimethylArginine (ADMA), based on a recognize biochemical parameter, the dilation of the brachial artery, at ultrasound examination, after the deflation of a cushion to evaluate artery dysfunction (vascular suffering) in growth diseases, growth hormone deficiency (GHD) and intrauterine growth retardation (IUGR) Secondary objectives: * Comparison of ADMA plasma concentrations with dose of matched healthy control children * Investigation of the mechanisms of arterial dysfunction, inflammation, oxidative stress and insulin resistance.

Conditions

• Growth Hormone Deficiency
• Small-for-gestational Age

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	arterial doppler ultrasound	doppler ultrasound

Timeline

• Start date: 2014-06-01
• Primary completion: 2018-12-31
• Completion: 2018-12-31
• First posted: 2018-02-05
• Last updated: 2025-12-16

Locations

2 sites across 1 country: France